Nanobiotix FY2024 EPS Estimate Lifted by Leerink Partnrs

Nanobiotix S.A. (NASDAQ:NBTX) – Stock analysts at Leerink Partnrs increased their FY2024 earnings estimates for Nanobiotix in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of ($0.94) per share for the year, up from their prior estimate of ($1.22). The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share. Leerink Partnrs also issued estimates for Nanobiotix’s FY2025 earnings at ($0.51) EPS and FY2026 earnings at $0.84 EPS.

Separately, UBS Group upgraded shares of Nanobiotix to a “hold” rating in a research report on Monday, February 17th.

Nanobiotix Stock Performance

Shares of NBTX opened at $3.62 on Friday. The company has a 50-day moving average of $3.51 and a two-hundred day moving average of $3.91. Nanobiotix has a 12-month low of $2.76 and a 12-month high of $7.51.

Hedge Funds Weigh In On Nanobiotix

Institutional investors have recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Nanobiotix in the fourth quarter valued at approximately $39,000. Jane Street Group LLC acquired a new position in Nanobiotix during the fourth quarter worth approximately $73,000. Geode Capital Management LLC acquired a new position in Nanobiotix during the fourth quarter worth approximately $29,000. Finally, OLD Mission Capital LLC acquired a new position in Nanobiotix during the fourth quarter worth approximately $139,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.